Search results
Results from the WOW.Com Content Network
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
8 AMAG: New hot rolling mill in Ranshofen puts AMAG in the top league. (No longer available online.) In: www.AMAG.at. AMAG, November 25, 2014, archived from the original on April 9, 2018; retrieved April 9, 2018. 9 AMAG: AMAG opens Europe's most modern aluminum cold rolling mill. In: www.AMAG.at. AMAG, June 23, 2017; retrieved April 9, 2018.
For premium support please call: 800-290-4726 more ways to reach us
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013. [5] In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. [6] In June 2015, the company acquired Cord Blood Registry for $700 million. [7] In 2014, AMAG acquired Lumara Health, formerly KV ...
AMAG Pharmaceuticals is a specialty biotech company that markets Feraheme (ferumoxytol), which is currently indicated only for the treatment of iron deficiency anemia (IDA) in adult chronic kidney ...